Overview

Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet

Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the relative bioavailability, or the degree and rate at which the drug is absorbed by the body of two cenobamate formulations (200 mg Oral Suspension and a 200 mg Oral Tablet) and to assess the effect of food on the oral bioavailability of the 200 mg Oral Suspension. This study will also look at the safety and tolerability of the oral suspension and the oral tablet under both fasted and fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
SK Life Science, Inc.
Treatments:
Cenobamate